<DOC>
	<DOCNO>NCT00272948</DOCNO>
	<brief_summary>The aim trial evaluate whether prophylactic use Defibrotide ( DF ) pediatric patient ( age le 18 year ) undergo stem cell transplantation high risk develop hepatic Veno-occlusive Disease ( VOD ) impact incidence severity disease . Patients randomly assign one two treatment arm : Those allocate Prophylactic Arm receive study drug ( Defibrotide ) day condition onwards . Patients allocate Control Arm receive study drug ( Defibrotide ) day VOD diagnose .</brief_summary>
	<brief_title>Pediatric Trial Investigating Incidence &amp; Outcome Veno-Occlusive Disease With Prophylactic Use Defibrotide</brief_title>
	<detailed_description>Comparison/control intervention duration intervention : Patients assign randomly either Defibrotide ( DF ) prophylaxis arm control arm . Those allocated DF prophylaxis arm ( DF 25 mg/kg/d iv 4 dos ) begin treatment day condition stop day +30 Stem Cell Transplantation ( SCT ) upon discharge inpatient care . There dose adjustment patient study arm develop VOD , continue 25mg/kg/d iv . Patients allocate control arm receive prophylactic measure start DF ( 25 mg/kg/d iv 4 dos ) begin day diagnosis Veno-occlusive Disease ( VOD ) accord modify Seattle criterion . Treatment stop complete resolution symptom . In arm patient develop VOD continue DF : - complete resolution ascites - reversion hepatopedal flow ( present ) - normalization total direct bilirubin</detailed_description>
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Age &lt; 18 year myeloablative conditioning autologous allogeneic stem cell transplantation least one follow risk factor VOD : 1 . Preexisting liver disease 2 . Second myeloablative HSCT 3 . History treatment gemtuzumab ozogamicin ( MYLOTARGÃ’ , GO , CMA676 , Wyeth ) 4 . Allogeneic HSCT leukemia beyond second relapse 5 . Osteopetrosis ( OP ) 6 . Conditioning busulfan melphalan 7 . Macrophage activate syndrome ( MAS , like hemophagocytic lymphohistiocytosis , Griscelli , ChediakHigashi 8 . Adrenoleukodystrophy ( ALD ) Pregnant patient Patients transplant fulfill mention criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Venoocclusive disease</keyword>
	<keyword>Pediatric</keyword>
	<keyword>myeloablative conditioning</keyword>
	<keyword>stem cell transplant</keyword>
</DOC>